Log In
BCIQ
Print this Print this
 

IMAB027

  Manage Alerts
Collapse Summary General Information
Company Ganymed Pharmaceuticals AG
DescriptionMAb against claudin-6 (CLDN6)
Molecular Target Claudin 6 (CLDN6)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationOvarian cancer
Indication DetailsTreat advanced ovarian cancer
Regulatory Designation EU - Orphan Drug (Treat advanced ovarian cancer)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today